Juan Ramon  Alaix net worth and biography

Juan Alaix Biography and Net Worth

Director of Zoetis
Juan Ramón Alaix was appointed chief executive officer of Zoetis in July 2012. In this role, he leads the world’s largest company with a singular focus on animal health medicines and vaccines. He is a member of the Zoetis Board of Directors.

Mr. Alaix served as President of Pfizer Animal Health since 2006, where he was responsible for theoverall strategic direction and financial performance of the company. Under his leadership, the company generated annual revenue of $4.8 billion in 2015 with approximately 9,000 employees worldwide. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries.
He joined Pfizer from Pharmacia in 2003 as Regional President. He has 35 years’ experience of increasing responsibility in finance, commercial and management, including 20 years in the pharmaceutical industry. In the 1990s, Mr. Alaix served in general management with Rhône-Poulenc Rorer in Spain and Belgium before becoming country President of Spain for Pharmacia in 1998.

In 2013, Mr. Alaix completed a two-year term as President of the International Federation for Animal Health (IFAH), now known as HealthforAnimals, in addition to serving as a member of the board and executive committee. HealthforAnimals represents manufacturers of veterinary medicines, vaccines and other animal health products in both developed and emerging markets. Mr. Alaix continues to serve as a member of the HealthforAnimals board and executive committee.

A native of Spain, Mr. Alaix received a graduate degree in economics from the Universidad de Madrid.

What is Juan Ramon Alaix's net worth?

The estimated net worth of Juan Ramon Alaix is at least $4.51 million as of November 13th, 2020. Mr. Alaix owns 26,694 shares of Zoetis stock worth more than $4,514,489 as of March 29th. This net worth estimate does not reflect any other assets that Mr. Alaix may own. Learn More about Juan Ramon Alaix's net worth.

How do I contact Juan Ramon Alaix?

The corporate mailing address for Mr. Alaix and other Zoetis executives is 10 Sylvan Way, Parsippany NJ, 07054. Zoetis can also be reached via phone at (973) 822-7000 and via email at [email protected]. Learn More on Juan Ramon Alaix's contact information.

Has Juan Ramon Alaix been buying or selling shares of Zoetis?

Juan Ramon Alaix has not been actively trading shares of Zoetis during the last ninety days. Most recently, Juan Ramon Alaix sold 91,747 shares of the business's stock in a transaction on Friday, November 13th. The shares were sold at an average price of $165.46, for a transaction totalling $15,180,458.62. Following the completion of the sale, the director now directly owns 26,694 shares of the company's stock, valued at $4,416,789.24. Learn More on Juan Ramon Alaix's trading history.

Who are Zoetis' active insiders?

Zoetis' insider roster includes Juan Alaix (Director), Heidi Chen (EVP), Glenn David (EVP), Andrew Fenton (EVP), Wetteny Joseph (Exec. VP & CFO ), Robert Kelly (EVP), Catherine Knupp (EVP), Roxanne Lagano (EVP), Clinton Lewis, Jr. (EVP), Gregory Norden (Director), Kristin Peck (CEO), Robert Polzer (EVP), Willie Reed (Director), Linda Rhodes (Director), Robert Scully (Director), and Roman Trawicki (EVP). Learn More on Zoetis' active insiders.

Are insiders buying or selling shares of Zoetis?

In the last twelve months, insiders at the sold shares 13 times. They sold a total of 49,823 shares worth more than $8,985,800.22. The most recent insider tranaction occured on March, 18th when EVP Roxanne Lagano sold 923 shares worth more than $159,983.59. Insiders at Zoetis own 0.1% of the company. Learn More about insider trades at Zoetis.

Information on this page was last updated on 3/18/2024.

Juan Ramon Alaix Insider Trading History at Zoetis

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/13/2020Sell91,747$165.46$15,180,458.6226,694View SEC Filing Icon  
2/19/2020Sell63,046$144.03$9,080,515.38159,059View SEC Filing Icon  
11/19/2019Sell50,000$119.13$5,956,500.00146,013View SEC Filing Icon  
2/28/2019Sell312,109$94.06$29,356,972.54View SEC Filing Icon  
11/8/2018Sell150,306$94.96$14,273,057.76246,319View SEC Filing Icon  
8/14/2018Sell135,000$91.55$12,359,250.00View SEC Filing Icon  
See Full Table

Juan Ramon Alaix Buying and Selling Activity at Zoetis

This chart shows Juan Ramon Alaix's buying and selling at Zoetis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Zoetis Company Overview

Zoetis logo
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
Read More

Today's Range

Now: $169.12
Low: $167.41
High: $171.14

50 Day Range

MA: $185.92
Low: $165.71
High: $199.94

2 Week Range

Now: $169.12
Low: $151.03
High: $201.92

Volume

3,395,584 shs

Average Volume

3,983,741 shs

Market Capitalization

$77.43 billion

P/E Ratio

33.36

Dividend Yield

1.03%

Beta

0.87